Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550699 | 1.00 | FFAR4 (0.45) | FFAR4CXCR3HSD11B1CYP3A4USP2 | |
| SCHEMBL551030 | 1.00 | FFAR4 (0.45) | FFAR4CXCR3HSD11B1CYP3A4USP2 | |
| SCHEMBL2698314 | 1.00 | FFAR4 (0.45) | FFAR4CXCR3HSD11B1CYP3A4USP2 | |
| SCHEMBL551029 | 1.00 | FFAR4 (0.45) | FFAR4CXCR3HSD11B1CYP3A4USP2 | |
| SCHEMBL550700 | 1.00 | FFAR4 (0.45) | FFAR4CXCR3HSD11B1CYP3A4USP2 | |
| SCHEMBL549769 | 0.90 | HSD11B1 (0.38) | FFAR4HSD11B1 | |
| SCHEMBL550413 | 0.90 | HSD11B1 (0.38) | FFAR4HSD11B1 | |
| SCHEMBL550412 | 0.90 | HSD11B1 (0.38) | FFAR4HSD11B1 | |
| SCHEMBL2701197 | 0.90 | HSD11B1 (0.38) | FFAR4HSD11B1 | |
| SCHEMBL549770 | 0.90 | HSD11B1 (0.38) | FFAR4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | FFAR4 3238/4885CXCR3 1144/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.